1996
DOI: 10.1172/jci118690
|View full text |Cite
|
Sign up to set email alerts
|

Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

Abstract: FK506 is a powerful immunosuppressive drug currently in use that inhibits the activation of several transcription factors (nuclear factor (NF)-AT and NF-B) critical for T cell activation. We show here that, contrary to the situation in T cells, FK506 activates transcription factor NF-B in nonlymphoid cells such as fibroblasts and renal mesangial cells. We further show that FK506 induces NF-B-regulated IL-6 production in vitro and in vivo, in particular in kidney. IL-6 has been shown previously to produce renal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
2

Year Published

1997
1997
2011
2011

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(33 citation statements)
references
References 32 publications
1
30
2
Order By: Relevance
“…Interestingly, FK506 has recently been reported to induce NF-B activation and concomitant proinflammatory cytokine expression in renal mesangial cells and fibroblasts. 79 The correlation of increasing NF-B activity shown in KCs with higher tacrolimus trough levels in the current study support evidence of a tacrolimus-induced activation of NF-B. Further investigations with a larger sample size are warranted to confirm the preliminary observations of heightened intragraft NF-B activation observed under tacrolimus versus CsA.…”
Section: Discussionsupporting
confidence: 76%
“…Interestingly, FK506 has recently been reported to induce NF-B activation and concomitant proinflammatory cytokine expression in renal mesangial cells and fibroblasts. 79 The correlation of increasing NF-B activity shown in KCs with higher tacrolimus trough levels in the current study support evidence of a tacrolimus-induced activation of NF-B. Further investigations with a larger sample size are warranted to confirm the preliminary observations of heightened intragraft NF-B activation observed under tacrolimus versus CsA.…”
Section: Discussionsupporting
confidence: 76%
“…Interstitial fibrosis caused by CsA is associated with increased expression of TGF-␤1 (56), and TGF-␤1 is responsive to induction by IL-1 in macrophages, which activates NF-B and several other transcription factors (57). IL-6 has been reported to contribute to nephrotoxicity (58,59), and FK506 induces IL-6 production in fibroblasts through the activation of NF-B (60). A role for FK506-induced NF-B activation in inducing nephrotoxicity was shown by a study in rats of chronic FK506 nephropathy, in which the NF-B inhibitor pyrrolidine dithiocarbamate reduced FK506-induced monocyte/macrophage infiltration, tubular injury, and intestinal fibrosis, which are hallmarks of nephrotoxicity (61).…”
Section: Discussionmentioning
confidence: 99%
“…We previously showed that FK506 induces IB␣ degradation and NF-B activation in nonlymphoid cells such as renal mesangial cells and fibroblasts. We further showed that, as a result of NF-B activation by FK506, interleukin-6 production is induced in the kidney, suggesting the possibility of a causal relationship between the FK506-induced NF-B activation/IL-6 production and some FK506-induced renal abnormalities (18). However, little is known about how FK506 induces IB␣ degradation in nonlymphoid cells.…”
Section: Nuclear Factor B (Nf-b)mentioning
confidence: 84%
“…Induces the Degradation of IB␣ and IB␤-To analyze the effects of FK506 stimulation on IB degradation, HAtagged IB␣ expression vectors were transfected into L-TK cells, which were most efficient in FK506-mediated NF-B activation (18). Cells were then treated with IL-1 or FK506 for different periods of time.…”
Section: Fk506mentioning
confidence: 99%